ACB Stock – Brokerages Expect Aurora Cannabis Inc. (NYSE:ACB) Will Announce Earnings of -$0.21 Per Share
Analysts predict that Aurora Cannabis Inc. (NYSE:ACB) will report earnings per share of ($0.21) for the current quarter, Zacks reports. Five analysts have made estimates for Aurora Cannabis’ earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.32). Aurora Cannabis posted earnings of ($0.13) per share in the same quarter last year, which would suggest a negative year over year growth rate of 61.5%. The business is expected to issue its next quarterly earnings results on Thursday, September 23rd.
On average, analysts expect that Aurora Cannabis will report full year earnings of ($2.70) per share for the current fiscal year, with EPS estimates ranging from ($3.15) to ($2.38). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.58) per share, with EPS estimates ranging from ($0.76) to ($0.40). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Aurora Cannabis.
Aurora Cannabis (NYSE:ACB) last posted its quarterly earnings data on Wednesday, May 12th. The company reported ($0.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.65). Aurora Cannabis had a negative net margin of 895.36% and a negative return on equity of 11.19%.
A number of research analysts have issued reports on the stock. Cantor Fitzgerald reduced their target price on shares of Aurora Cannabis from $11.25 to $9.00 and set a “neutral” rating for the company in a research note on Friday, May 14th. Zacks Investment Research raised Aurora Cannabis from a “sell” rating to a “hold” rating in a research note on Wednesday, May 19th. Bank of America began coverage on shares of Aurora Cannabis in a report on Wednesday, April 28th. They issued a “neutral” rating for the company. Needham & Company LLC initiated coverage on shares of Aurora Cannabis in a research note on Friday, May 14th. They set a “sell” rating on the stock. Finally, Canaccord Genuity reaffirmed a “sell” rating and issued a $7.00 price target (down from $14.00) on shares of Aurora Cannabis in a research note on Thursday, May 20th. Six analysts have rated the stock with a sell rating and eight have issued a hold rating to the company. Aurora Cannabis currently has a consensus rating of “Hold” and an average target price of $8.22.
Several institutional investors have recently bought and sold shares of the company. Mackenzie Financial Corp lifted its stake in Aurora Cannabis by 5.4% in the fourth quarter. Mackenzie Financial Corp now owns 13,621 shares of the company’s stock valued at $113,000 after acquiring an additional 700 shares during the last quarter. US Bancorp DE raised its holdings in shares of Aurora Cannabis by 23.0% during the 4th quarter. US Bancorp DE now owns 6,018 shares of the company’s stock valued at $50,000 after purchasing an additional 1,125 shares in the last quarter. Shell Asset Management Co. boosted its holdings in Aurora Cannabis by 6.7% in the first quarter. Shell Asset Management Co. now owns 19,018 shares of the company’s stock worth $177,000 after purchasing an additional 1,192 shares in the last quarter. AdvisorShares Investments LLC increased its position in Aurora Cannabis by 7.8% during the first quarter. AdvisorShares Investments LLC now owns 18,328 shares of the company’s stock worth $171,000 after buying an additional 1,334 shares during the last quarter. Finally, Advisory Services Network LLC raised its stake in shares of Aurora Cannabis by 87.6% in the 4th quarter. Advisory Services Network LLC now owns 3,005 shares of the company’s stock valued at $25,000 after acquiring an additional 1,403 shares in the last quarter. Institutional investors and hedge funds own 12.89% of the company’s stock.
Aurora Cannabis stock opened at $8.73 on Friday. The company has a quick ratio of 4.95, a current ratio of 5.88 and a debt-to-equity ratio of 0.19. Aurora Cannabis has a one year low of $3.71 and a one year high of $18.98. The business’s 50-day moving average price is $8.59. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -0.59 and a beta of 3.20.
Aurora Cannabis Company Profile
Aurora Cannabis Inc produces and distributes medical cannabis products worldwide. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, including facility engineering and design, cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Featured Article: Margin
Get a free copy of the Zacks research report on Aurora Cannabis (ACB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
NYSE&Symbol=ACB” alt=”Earnings History and Estimates for Aurora Cannabis (NYSE:ACB)” width=”650″ height=”325″/>
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Systematic Risk and Investors
7 Healthcare Stocks Delivering Innovation in 2021
We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.
Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.
However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.
That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.
View the “7 Healthcare Stocks Delivering Innovation in 2021”.